Epigenetic Modification in the Expression of P73 P73 - Epigenetic Target for Anticancer Therapy

Overview

Journal Oncol Rev

Specialty Oncology

Date 2019 Aug 15

PMID 31410249

Citations 1

Authors

Faiza Naseer

Mohammad Saleem

Affiliations

Soon will be listed here.

Abstract

A p73 is a new member of p53 family of transcription factor, having two types. First is TAp73, transcriptionally active and expressed upstream promoter as a tumor suppressor and vital apoptotic inductor, it also has a key role in cell cycle arrest/differentiation and Second is ΔNp73 that is transcriptionally inactive and expressed downstream regulator as oncogenes. Both types are expressed in various isoforms, which originate from alternative splicing events at the C-terminus. Upon DNA damage, posttranslational modifications cause conformational changes in various amino acid residues induction or inhibition of various proteins, which are present in the structural domains of p73. These modifications may cause up- or down-regulation of p73 expression levels, as well as alters the transcriptional activity and/or stability of the protein. In this review, we have made an effort to assemble all existing data regarding the role of p73, its modification and after effects in cancer.

Citing Articles

The p53 Protein Family in the Response of Tumor Cells to Ionizing Radiation: Problem Development.

Kuchur O, Kuzmina D, Dukhinova M, Shtil A Acta Naturae. 2021; 13(3):65-76.

PMID: 34707898 PMC: 8526179. DOI: 10.32607/actanaturae.11247.

References

Putzer B, Stiewe T, Parssanedjad K, Rega S, Esche H . E1A is sufficient by itself to induce apoptosis independent of p53 and other adenoviral gene products. Cell Death Differ. 2000; 7(2):177-88. DOI: 10.1038/sj.cdd.4400618. View

Minty A, Dumont X, Kaghad M, Caput D . Covalent modification of p73alpha by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif. J Biol Chem. 2000; 275(46):36316-23. DOI: 10.1074/jbc.M004293200. View

Irwin M, Marin M, Phillips A, Seelan R, Smith D, Liu W . Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature. 2000; 407(6804):645-8. DOI: 10.1038/35036614. View

Stiewe T, Putzer B . Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet. 2000; 26(4):464-9. DOI: 10.1038/82617. View

Wang J . Regulation of cell death by the Abl tyrosine kinase. Oncogene. 2000; 19(49):5643-50. DOI: 10.1038/sj.onc.1203878. View

Naka M, Ozaki T, Takada N, Takahashi M, Shishikura T, Sakiyama S . Functional characterization of naturally occurring mutants (P405R and P425L) of p73alpha and p73beta found in neuroblastoma and lung cancer. Oncogene. 2001; 20(27):3568-72. DOI: 10.1038/sj.onc.1204470. View

Deng G, Chen A, Pong E, Kim Y . Methylation in hMLH1 promoter interferes with its binding to transcription factor CBF and inhibits gene expression. Oncogene. 2001; 20(48):7120-7. DOI: 10.1038/sj.onc.1204891. View

Grob T, Novak U, Maisse C, Barcaroli D, Luthi A, Pirnia F . Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ. 2001; 8(12):1213-23. DOI: 10.1038/sj.cdd.4400962. View

Bird A . DNA methylation patterns and epigenetic memory. Genes Dev. 2002; 16(1):6-21. DOI: 10.1101/gad.947102. View

10.

Costanzo A, Merlo P, Pediconi N, Fulco M, Sartorelli V, Cole P . DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell. 2002; 9(1):175-86. DOI: 10.1016/s1097-2765(02)00431-8. View

11.

Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T, Ikawa S . Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res. 2002; 62(3):636-41. View

12.

Sanchez-Prieto R, Sanchez-Arevalo V, Servitja J, Gutkind J . Regulation of p73 by c-Abl through the p38 MAP kinase pathway. Oncogene. 2002; 21(6):974-9. DOI: 10.1038/sj.onc.1205134. View

13.

Watanabe K, Ozaki T, Nakagawa T, Miyazaki K, Takahashi M, Hosoda M . Physical interaction of p73 with c-Myc and MM1, a c-Myc-binding protein, and modulation of the p73 function. J Biol Chem. 2002; 277(17):15113-23. DOI: 10.1074/jbc.M111281200. View

14.

Stiewe T, Putzer B . Role of p73 in malignancy: tumor suppressor or oncogene?. Cell Death Differ. 2002; 9(3):237-45. DOI: 10.1038/sj.cdd.4400995. View

15.

Nakagawa T, Takahashi M, Ozaki T, Todo S, Mizuguchi H, Hayakawa T . Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter. Mol Cell Biol. 2002; 22(8):2575-85. PMC: 133713. DOI: 10.1128/MCB.22.8.2575-2585.2002. View

16.

Vossio S, Palescandolo E, Pediconi N, Moretti F, Balsano C, Levrero M . DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. Oncogene. 2002; 21(23):3796-803. DOI: 10.1038/sj.onc.1205465. View

17.

Allart S, Martin H, Detraves C, Terrasson J, Caput D, Davrinche C . Human cytomegalovirus induces drug resistance and alteration of programmed cell death by accumulation of deltaN-p73alpha. J Biol Chem. 2002; 277(32):29063-8. DOI: 10.1074/jbc.M201974200. View

18.

Ren J, Datta R, Shioya H, Li Y, Oki E, Biedermann V . p73beta is regulated by protein kinase Cdelta catalytic fragment generated in the apoptotic response to DNA damage. J Biol Chem. 2002; 277(37):33758-65. DOI: 10.1074/jbc.M110667200. View

19.

Kartasheva N, Contente A, Roth J, Dobbelstein M . p53 induces the expression of its antagonist p73 Delta N, establishing an autoregulatory feedback loop. Oncogene. 2002; 21(31):4715-27. DOI: 10.1038/sj.onc.1205584. View

20.

Melino G, De Laurenzi V, Vousden K . p73: Friend or foe in tumorigenesis. Nat Rev Cancer. 2002; 2(8):605-15. DOI: 10.1038/nrc861. View